MMI and SS Innovations Advance Robotic Surgery with Alzheimer’s and Telesurgery Breakthroughs

Medical Microinstruments (MMI) has received FDA approval for an investigational device exemption (IDE) to assess a microsurgical procedure for Alzheimer’s disease using its Symani robotic platform. The REMIND study will evaluate the safety and feasibility of improving neurotoxin drainage from the brain in patients with mild to moderate Alzheimer’s who have blocked cervical lymph nodes. Key measures include device-related safety events within 30 days and biomarker, imaging, and cognitive outcomes over six months. The Symani system, authorized by the FDA in 2024, enables precise manipulation of vessels as small as 0.2 mm.

Separately, SS Innovations International announced the first telesurgery using its compact SSi Mantra Tele Surgeon Console, enabling remote cardiac surgery. The smaller design, with 3D visualization and built-in electronics, broadens access to surgical expertise. SS Innovations plans a 510(k) FDA submission this year, following over 6,500 global procedures performed with its robotic system.

10-11-2025